BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Target Lowered at JPMorgan Chase & Co.

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target decreased by equities researchers at JPMorgan Chase & Co. from $87.00 to $86.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 50.89% from the stock’s previous close.

BMRN has been the subject of a number of other reports. Morgan Stanley lowered their price objective on shares of BioMarin Pharmaceutical from $122.00 to $119.00 and set an “overweight” rating for the company in a research report on Tuesday. Stifel Nicolaus cut their target price on shares of BioMarin Pharmaceutical from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Tuesday. Raymond James Financial raised shares of BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 target price on the stock in a research note on Monday, October 12th. Royal Bank Of Canada lowered their price target on shares of BioMarin Pharmaceutical from $62.00 to $60.00 and set a “sector perform” rating for the company in a report on Tuesday. Finally, Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.91.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock traded up $1.33 during midday trading on Wednesday, reaching $56.99. The company’s stock had a trading volume of 1,333,890 shares, compared to its average volume of 2,121,643. BioMarin Pharmaceutical has a 52 week low of $49.26 and a 52 week high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $60.24 and a 200-day moving average price of $58.45. The stock has a market cap of $11.03 billion, a PE ratio of -566.70, a price-to-earnings-growth ratio of 0.63 and a beta of 0.21.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.28. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. BioMarin Pharmaceutical had a positive return on equity of 5.59% and a negative net margin of 0.52%. The business’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.12 earnings per share. On average, sell-side analysts predict that BioMarin Pharmaceutical will post 2.59 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BMRN. Primecap Management Co. CA acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $811,962,000. Caisse de depot et placement du Quebec acquired a new position in shares of BioMarin Pharmaceutical in the second quarter worth approximately $70,749,000. Bank of New York Mellon Corp bought a new stake in BioMarin Pharmaceutical in the second quarter valued at approximately $66,107,000. Edmond DE Rothschild Holding S.A. bought a new stake in BioMarin Pharmaceutical in the second quarter valued at approximately $39,312,000. Finally, Palo Alto Investors LP acquired a new stake in BioMarin Pharmaceutical during the 2nd quarter valued at approximately $39,068,500. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Third-quarter revenue rose 32% year over year to $1.025 billion, in line with estimates, while earnings per share of $0.23 beat expectations. Growth was led by metabolic conditions, up 44%, and skeletal conditions, up 12%. Read More.
• Positive Sentiment: VOXZOGO remains a potential growth catalyst: BioMarin expects an FDA decision on its use for hypochondroplasia by May 30, 2027, which could expand its skeletal-disease franchise. The company also recently added an investigational Fabry asset. Read More.
• Positive Sentiment: An Seeking Alpha analysis argues that BMRN’s lower valuation, broader commercial portfolio and potential product expansion improve its risk-reward profile, while noting that the benefits of the Amicus acquisition still need to justify its financing costs. Read More.
• Neutral Sentiment: BioMarin plans to present at three investor conferences in November, providing management opportunities to discuss results and outlook. Read More.
• Negative Sentiment: The company lowered its full-year 2026 outlook: revenue is now forecast at $3.8–$3.9 billion, versus the $3.9 billion consensus, and EPS at $2.80–$3.10, below the $3.32 consensus. BioMarin cited order-timing uncertainty and charges for acquired in-process research and development, making the guidance cut a key near-term headwind. Read More.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.